On April 14, 2020, Five Prime Therapeutics, Inc. announced that Thomas Civik joined the Company as President and Chief Executive Officer and a member of the Board of Directors of the Company (the "Board"), effective as of April 13, 2020 (the "Commencement Date"). Mr. Civik will serve as a Class II member of the Board, to serve until the 2021 annual meeting of stockholders or until his successor is duly elected and qualified. Prior to joining the Company, from November 2017 until September 2019, Mr. Civik, 51, served as Chief Commercial Officer of Foundation Medicine, Inc. In connection with the Company's appointment of Mr. Civik as President and Chief Executive Officer of the Company, William R. Ringo resigned his position as interim Chief Executive Officer of the Company effective upon the start of Mr. Civik's employment on April 13, 2020.

Mr. Ringo will continue to serve as Chairman of the Board. The Company expects that Mr. Ringo will continue to serve as an employee of the Company until May 31, 2020, but on a part-time schedule during this transitionary period.